Revance Therapeutics (NASDAQ:RVNC) Now Covered by StockNews.com

Investment analysts at StockNews.com initiated coverage on shares of Revance Therapeutics (NASDAQ:RVNC) in a research note issued to investors on Thursday. The firm set a “hold” rating on the biopharmaceutical company’s stock.

Other analysts have also recently issued reports about the stock. Barclays restated an “equal weight” rating and set a $7.00 price objective (down from $10.00) on shares of Revance Therapeutics in a research note on Friday, September 13th. Mizuho decreased their price objective on shares of Revance Therapeutics from $6.66 to $3.10 and set a “neutral” rating for the company in a research note on Tuesday. HC Wainwright reaffirmed a “neutral” rating and set a $6.60 target price on shares of Revance Therapeutics in a report on Friday, November 8th. Finally, Needham & Company LLC reissued a “hold” rating on shares of Revance Therapeutics in a report on Friday, November 8th. Nine research analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $8.96.

Revance Therapeutics Trading Up 0.5 %

Shares of NASDAQ RVNC opened at $3.04 on Thursday. Revance Therapeutics has a 12 month low of $2.30 and a 12 month high of $9.74. The company has a 50 day simple moving average of $4.64 and a two-hundred day simple moving average of $4.47. The stock has a market cap of $318.90 million, a price-to-earnings ratio of -1.58 and a beta of 0.82.

Revance Therapeutics (NASDAQ:RVNC) last announced its quarterly earnings data on Thursday, November 7th. The biopharmaceutical company reported ($0.37) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.02). The business had revenue of $59.88 million for the quarter, compared to analyst estimates of $67.73 million. Analysts forecast that Revance Therapeutics will post -1.54 EPS for the current year.

Institutional Investors Weigh In On Revance Therapeutics

Large investors have recently modified their holdings of the business. Certuity LLC purchased a new stake in shares of Revance Therapeutics during the second quarter worth $26,000. Vanguard Personalized Indexing Management LLC purchased a new stake in shares of Revance Therapeutics during the second quarter worth $33,000. Hsbc Holdings PLC purchased a new stake in shares of Revance Therapeutics during the second quarter worth $38,000. Nisa Investment Advisors LLC grew its holdings in shares of Revance Therapeutics by 2,167.5% during the second quarter. Nisa Investment Advisors LLC now owns 18,911 shares of the biopharmaceutical company’s stock worth $49,000 after buying an additional 18,077 shares in the last quarter. Finally, FORA Capital LLC purchased a new stake in shares of Revance Therapeutics during the third quarter worth $54,000. Hedge funds and other institutional investors own 97.70% of the company’s stock.

Revance Therapeutics Company Profile

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company’s lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.